RxDoctor Payments Data

Jill Schaeffer

Critical Care Medicine · Lancaster, PANPI 1386626042

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Irhythm Technologies, Inc. at 25.0% of the total. Reporting peaked in 2024 at $2,096 and has fallen 74.3% since, to $539 in 2025.

$4,201in general payments, 2019–2025

Across 26 payments — averaging $161.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$1K
  • Medtronic$965
  • Abbott$801
  • Impulse Dynamics (USA) Inc.$600
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$234
  • Boston Scientific$138
  • plus $413 from 6 others

What the payments were for

  • Consulting fees$2,10050%
  • Food & beverage$2,10150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,201 in reported general payments places this provider in the 85th percentile of 354 critical care medicine providers in Pennsylvania.

See all critical care medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,113
Medicare patients
187
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban705$824,795
EntrestoSacubitril/Valsartan126$173,589
XareltoRivaroxaban121$158,983
JardianceEmpagliflozin131$133,216
Repatha SureclickEvolocumab92$97,665
MultaqDronedarone Hcl31$50,734
FarxigaDapagliflozin Propanediol34$36,426
BrilintaTicagrelor24$21,512
Metoprolol Succinate751$12,320
Praluent PenAlirocumab14$10,205
Sildenafil Citrate14$10,177
VascepaIcosapent Ethyl13$9,954
Dofetilide49$9,536
Icosapent Ethyl17$5,871
Atorvastatin Calcium520$5,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$824,795705 claims
NovartisEntresto$47$173,589126 claims
Sanofi-aventis U.S. LLCMultaq$89$50,73431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 354 critical care medicine providers in Pennsylvania.

Other critical care medicine in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →